GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Hypertension Diagnostics HDII · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2022

Revenue

—

FY2016FY2022

Net income

−$93,247

FY2016FY2022

Free cash flow

−$892,257

FY2016FY2022

Shareholders' equity

—

FY2016FY2022

Income statement

Fiscal years

FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue———$3.8m$3.8m$3.7m$3.6m
Gross profit———$954,474$954,500$752,388$551,189
Operating income−$121,900−$11,000−$419,990−$420,000$700−$403,495−$656,000
Net income−$93,247−$11,000$3.3m$3.3m−$125,400−$368,611−$622,000
Diluted earnings per share-0.00-0.000.020.02-0.00-0.00-0.00

Balance sheet

At each fiscal year end

FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets—$1.1m$1.1m$1.1m$1.3m$1.5m$1.4m
Cash and short-term investments—$86,392$86,392$86,392$86,400$285,434$190,198
Total liabilities$121,895$2.0m$2.1m$2.1m$6.0m$6.1m$5.7m
Debt—$651,319$775,000$775,000$4.7m$4.4m$4.2m
Shareholders' equity—−$913,707−$1.0m−$1.0m−$4.8m−$4.6m−$4.3m
Shares outstanding285m285m149m137m52m285m285m

Cash flow

Fiscal years

FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$892,257−$11,000$3.5m$3.5m−$386,300−$85,919−$384,938
Capital spending———−$2,111−$2,100−$2,033−$1,959
Free cash flow−$892,257−$11,000$3.5m$3.5m−$388,400−$87,952−$386,897

Latest quarters

By quarter end

Mar 2022Dec 2021Sept 2021Jun 2021Dec 2020Sept 2020Jun 2020Mar 2020
Operating income−$717,000−$717,440−$32,650−$32,650−$5,500−$5,500−$5,500−$5,500
Net income−$717,000−$717,437−$32,650−$32,650−$5,500−$5,500−$5,500−$5,500
Diluted earnings per share-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00
Total assets———$1.1m$1.1m$1.1m——
Cash and short-term investments———$86,392$86,392$86,392——
Shareholders' equity———−$262,388−$913,707−$913,707——

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-33.8%-21.3%-7.4%
Net income—-24.0%-9.3%

Valuation history

At each fiscal year end

FY2021
Price to earnings-0.1

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return100%100%1814%-71%-62%149%5982%22833%913%385%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.